VLU Dressing Study
NCT03621592
Recruiting
The goal of the study is to investigate the effectiveness of Cutimed Sorbact (Study Device) in modifying bacterial load in venous leg ulcers (VLU).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2025
Locations: University of Miami, Miami, Florida
Conditions: Venous Leg Ulcer
Register for Updates
The Role of Type 2 Diabetes on Skeletal Muscle Atrophy and Recovery Following Bed Rest in Older Adults
NCT03761446
Recruiting
The goal of this study is to determine the impact of pre-diabetes and type 2 diabetes on muscle atrophy during a period of bed rest and recovery of muscle mass, strength, and physical function following bed rest.
Gender:
ALL
Ages:
Between 60 years and 80 years
Trial Updated:
03/12/2025
Locations: Translational Research Institute for Metabolism and Diabetes, Orlando, Florida
Conditions: Muscle Atrophy, Aging, Sedentary Behavior, Type 2 Diabetes, Pre-diabetes
Register for Updates
Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis
NCT03844061
Recruiting
This is a 52 week, single center, randomized, double-blind, placebo-controlled study. After patients maintain a stable dose of Mycophenolate Mofetil (MMF) for at least 1 month, they will be randomized to treatment with either Belimumab \& Rituximab or placebo.Patients in both groups will be on background MMF for the entirety of the study. Belimumab will be administered subcutaneously and Rituximab intravenously. Placebo injections and infusions will be of normal saline. Randomization will be do... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
03/12/2025
Locations: Hospital for Special Surgery, New York, New York
Conditions: Systemic Sclerosis
Register for Updates
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
NCT03851445
Recruiting
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2025
Locations: Veterans Administration Medical Center - Birmingham, Birmingham, Alabama +1159 locations
Conditions: Previously Treated Non-Small Cell Lung Cancer
Register for Updates
Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases
NCT03965234
Recruiting
This phase I/II trial studies the side effects of pulmonary suffusion in controlling minimal residual disease in patients with sarcoma or colorectal carcinoma that has spread to the lungs. Pulmonary suffusion is a minimally invasive delivery of chemotherapeutic agents like cisplatin to lung tissues. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreadin... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2025
Locations: Roswell Park Cancer Institute, Buffalo, New York
Conditions: Metastatic Bone Sarcoma, Metastatic Malignant Neoplasm in the Lung, Metastatic Soft Tissue Sarcoma, Metastatic Unresectable Sarcoma, Resectable Sarcoma, Colorectal Cancer
Register for Updates
An Early Feasibility Study of the HighLife 28mm Trans-Septal Transcatheter Mitral Valve Replacement System
NCT04029337
Recruiting
Study to evaluate the feasibility, safety and performance of the HighLife trans-septal Transcatheter Mitral Valve in patients with moderate-severe and severe mitral regurgitation who are at high risk for surgical treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2025
Locations: Tucson Medical Center, Tucson, Arizona +9 locations
Conditions: Mitral Regurgitation
Register for Updates
Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors
NCT04074135
Recruiting
Background: People with von Hippel-Lindau (VHL) can have problems with a variety of organs, such as the pancreas. The disease can cause tumors of the pancreas. This can result in life-threatening complications. Researchers want to learn more about these pancreatic tumors and how to better detect them. This may help them design better future treatment and care for people with VHL disease. Objective: To better understand VHL disease that affects the pancreas and to test whether adding a certain... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
03/12/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: VHL Pancreatic Neuroendocrine Tumors, Von Hippel-Lindau Disease, Neuroendocrine Tumors
Register for Updates
Psoriatic Arthritis D2P Screening
NCT04110522
Recruiting
The overarching goal of this study is to develop a direct-to-patient screening approach that will improve early Psoriatic Arthritis (PsA) detection in patients with psoriasis. Previously developed screening questionnaires were intended for use in the setting of a doctor's office to assist providers with referral decisions. However, these screening questionnaires are infrequently used in routine practice because of limitations with time and resources. The study will aim to develop a practical scr... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania +1 locations
Conditions: Psoriatic Arthritis
Register for Updates
GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas(DIPG) & Spinal Diffuse Midline Glioma(DMG)
NCT04196413
Recruiting
The primary purpose of this study is to test whether GD2-CAR T cells can be successfully made from immune cells collected from children and young adults with H3K27M-mutant diffuse intrinsic pontine glioma (DIPG) or spinal H3K27M-mutant diffuse midline glioma (DMG). H3K27Mmutant testing will occur as part of standard of care prior to enrollment.
Gender:
ALL
Ages:
Between 2 years and 60 years
Trial Updated:
03/12/2025
Locations: Lucile Packard Children's Hospital (LPCH), Stanford, California
Conditions: Glioma of Spinal Cord, Glioma of Brainstem
Register for Updates
Prospective Randomized Blinded Trial of VersaWrap Tendon Protector for Zone 2 Flexor Tendon Injuries
NCT04322370
Recruiting
To analyze outcomes between patients with Z2FT injuries following repair, randomized to two groups. The first group will be the negative control, with no tendon wrap. The second group will have a VersaWrap Tendon Protector applied over the site of the tendon repair. VersaWrap is current SOC at UF.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
03/12/2025
Locations: University of Florida, Gainesville, Florida
Conditions: Flexor Tendon
Register for Updates
Investigating the Effects of Aerobic and Resistance Training in Vivo on Skeletal Muscle Metabolism in Vitro in Primary Human Muscle Cells (MoTrMyo)
NCT04334343
Recruiting
The goal of the study is to examine the ability of resistance or aerobic exercise training to "imprint" skeletal muscle cells in a manner which confers long-term changes in this tissue which in-turn contribute to improved metabolic health and functional capacity through epigenetic regulation of novel exercise response genes. This study will also provide primary human skeletal muscle cells to the Molecular Transducers of Physical Activity Consortium (MoTrPAC) (NCT03960827) repository for future u... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2025
Locations: AdventHealth Translational Research Institute, Orlando, Florida
Conditions: Physical Activity
Register for Updates
Study of Sonodynamic Therapy in Participants with Recurrent High-Grade Glioma
NCT04559685
Recruiting
A Phase 0 single center, first in human, open-label study of ascending energy doses of sonodynamic therapy (SDT) utilizing the MRgFUS combined with intravenous ALA to assess safety and efficacy in up to 45 participants with recurrent HGG. Eligible participants who are scheduled for resection will be administered intravenous (IV) aminolevulinic acid HCl (ALA) approximately six to seven (6-7) hours prior to receiving sonodynamic therapy (SDT).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2025
Locations: St. Joseph's Hospital and Medical Center, Phoenix, Arizona
Conditions: High Grade Glioma
Register for Updates